Why Gene Therapy Is More Cost Effective Than Biogen's Approved Drug [Investor's Business Daily]
Ionis Pharmaceuticals, Inc. (IONS)
Last ionis pharmaceuticals, inc. earnings: 2/26 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ionispharma.com
Company Research
Source: Investors Business Daily
Related news An experimental gene therapy from Novartis ( NVS ) will be more cost effective than Biogen ( BIIB ) and Ionis Pharmaceuticals ' ( IONS ) treatment for a muscle-wasting disease, experts said this week. Biogen and Ionis grabbed approval for Spinraza in late 2016. So far, it's the only drug on the market in the U.S. to treat spinal muscular atrophy , a genetic disease of the nerves that control muscles. But Novartis is hoping to follow in 2019 with its gene therapy called Zolgensma. If priced at the $2 million mark, Zolgensma is more cost effective than Spinraza, experts with the Institute for Clinical and Economic Review said in a report late Thursday. "These findings could offer support for Novartis in pricing and access negotiations for Zolgensma ahead of the 2019 estimated approval," Leerink analyst Geoffrey Porges said in a report to clients on Friday. The report measures disease burden over time. It uses a metric called a quality-adjusted life year . One quality-adjust
Show less
Read more
Impact Snapshot
Event Time:
IONS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IONS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IONS alerts
High impacting Ionis Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
IONS
News
- n-Lorem Foundation Partners with Hongene Biotech Corporation to Support the Discovery of Personalized ASO Medicines for Nano-rare Patients [Yahoo! Finance]Yahoo! Finance
- Ionis to hold first quarter 2024 financial results webcastPR Newswire
- Bepirovirsen for Chronic Hepatitis B Drug Pipeline Report 2024: 7MM Market Size, Forecast, and Emerging Insights 2019-2032 [Yahoo! Finance]Yahoo! Finance
- n-Lorem Foundation Collaborates with Across Healthcare to Develop a Custom Submission Platform for Physicians of Nano-rare Patients [Yahoo! Finance]Yahoo! Finance
- n-Lorem Foundation Announces the Second Annual Nano-rare Patient Colloquium Will be Held on Oct. 30 & 31, 2024 [Yahoo! Finance]Yahoo! Finance
IONS
Earnings
- 2/21/24 - Beat
IONS
Sec Filings
- 4/17/24 - Form 4
- 4/17/24 - Form 4
- 4/16/24 - Form 144
- IONS's page on the SEC website